176032-78-3 Usage
Description
3-(1H-1,2,4-TRIAZOL-1-YL)ANILINE is an organic compound with the chemical structure featuring a triazole ring and an aniline group. It is a synthetic intermediate used in the development of various pharmaceuticals and chemical products.
Uses
Used in Pharmaceutical Industry:
3-(1H-1,2,4-TRIAZOL-1-YL)ANILINE is used as a key intermediate in the synthesis of N-(pyrimidinylaminophenyl) sulfonamides, which are known as ZAP-70 inhibitors. These inhibitors play a crucial role in the treatment of certain diseases by targeting the ZAP-70 protein, which is involved in the regulation of immune cell activation and proliferation.
In the preparation of N-(pyrimidinylaminophenyl) sulfonamides, 3-(1H-1,2,4-TRIAZOL-1-YL)ANILINE serves as a building block that contributes to the overall structure and activity of the final product. Its unique chemical properties allow for the development of potent and selective inhibitors, which can be beneficial in the treatment of various medical conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 176032-78-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,7,6,0,3 and 2 respectively; the second part has 2 digits, 7 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 176032-78:
(8*1)+(7*7)+(6*6)+(5*0)+(4*3)+(3*2)+(2*7)+(1*8)=133
133 % 10 = 3
So 176032-78-3 is a valid CAS Registry Number.
InChI:InChI=1/C8H8N4/c9-7-2-1-3-8(4-7)12-6-10-5-11-12/h1-6H,9H2
176032-78-3Relevant articles and documents
4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-3,6-DIHYDROPYRIDINE-1-(2H)-CARBOXAMIDE DERIVATIVES AS LIMK AND/OR ROCK KINASES INHIBITORS FOR USE IN THE TREATMENT OF CANCER
-
Paragraph 0131-0132, (2021/12/07)
The present invention concerns a compound of formula (I), in particular as LIMK and/or ROCK kinases inhibitors. The present invention also concerns these new inhibitors for use for the treatment of a condition selected in the group consisting of: cancers, virion infections, ocular hypertension and glaucoma formation, Neurofibromatosis type 1 and 2, psoriatic lesions, inflammatory diseases and hyperalgesia, central sensitization and chronic pain, reproduction erectile dysfunction, and neuronal diseases. The present description discloses the syntheses and characterisation of exemplary compounds as well as pharmacological data thereof (e.g. pages 32 to 127; examples 1 to 96; families 1 to 8; compounds; biological studies; tables). An exemplary compound is e.g. 4-(5-m ethyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-N-phenyl-3,6-dihydropyridine-1-(2H)-carboxamide (example 1; compound 5).